Tesamorelin: Mechanism, Research Applications & Availability in Thailand
Tesamorelin (Egrifta) explained: how the GHRH(1-44) analogue drives visceral fat research, its Phase 3 trial data, and how researchers source it in Thailand.
Tesamorelin is a stabilised analogue of full-length growth-hormone-releasing hormone, GHRH(1-44), marketed clinically as Egrifta, and is available to researchers in Thailand, including Bangkok, as a lab-tested research vial. It is the only GHRH analogue with FDA approval, which makes it the most clinically documented compound in its class for research reference.
Researchers searching “tesamorelin Thailand” are typically looking for two different things at once: the mechanism behind its visceral-fat research data, and a straightforward path to sourcing a lab-tested vial locally. This guide covers both.
What Is Tesamorelin?
Tesamorelin carries a trans-3-hexenoic acid modification on the N-terminus of GHRH(1-44) that blocks DPP-IV enzymatic cleavage, extending its circulating half-life to roughly 26-38 minutes, long enough to bind the GHRH receptor on pituitary somatotrophs and trigger a pulsatile growth-hormone release. The released growth hormone raises hepatic IGF-1 output and acts on visceral adipocytes through GH-receptor and JAK2-STAT5 signalling, activating hormone-sensitive lipase and increasing lipolysis. Because the mechanism amplifies the body’s own GHRH pulse rather than introducing exogenous growth hormone, the resulting hormonal profile stays physiological and feedback-regulated.
Full mechanism detail and citations are on the Tesamorelin product page.
What the Clinical Data Shows
Tesamorelin’s Phase 3 programme is the most extensive of any GHRH analogue: two double-blind, randomised, placebo-controlled trials enrolled a combined total of more than 800 HIV-positive patients with lipodystrophy, using visceral adipose tissue (VAT) measured by CT scan as the primary endpoint. The active arm achieved roughly 15-18% VAT reduction against placebo by 26 weeks, alongside improvements in lipid profile (FDA review data, 2010, N Engl J Med; Falutz et al., 2010, J Acquir Immune Defic Syndr).
More recent research has extended into cognitive outcomes: a randomised trial in older adults with mild cognitive impairment reported improvements in executive function, verbal memory and overall cognitive composite scores, with the growth hormone/IGF-1 axis proposed as the underlying mechanism (Baker et al., 2019, J Clin Endocrinol Metab).
These are clinical-trial results in defined study populations under supervised protocols, not outcomes implied for anyone purchasing a research vial.
Tesamorelin Research Applications
The clinical approval is specific to HIV-associated lipodystrophy, but the underlying growth-hormone-driven lipolytic mechanism is not HIV-specific, which is why research interest extends further:
- Visceral adipose tissue reduction and tissue-selective lipolysis studies
- Growth hormone / IGF-1 axis research using a pulsatile GHRH stimulus
- Lipid-profile and cardiovascular risk-marker research
- Age-related growth hormone decline and body-composition research
- Cognitive function research in mild cognitive impairment models
Tesamorelin vs. CJC-1295
A common comparison question: tesamorelin is full-length GHRH(1-44) with an N-terminal modification giving a short (minutes-scale) half-life, while CJC-1295 is a shortened GHRH(1-29) fragment, and the DAC-conjugated version extends half-life to days rather than minutes. Both bind GHRH receptors with high affinity; the choice in a given protocol depends on whether pulsatile, short-acting signalling (tesamorelin) or sustained receptor engagement (CJC-1295 with DAC) is the variable under study.
Sourcing Tesamorelin in Thailand
As with other research peptides, tesamorelin is not stocked through Thai pharmacies for research purposes; it is sourced through specialist peptide suppliers shipping to Bangkok and other locations. The same due-diligence checklist applies: a batch-specific certificate of analysis, clear research-use labelling, traceable lot numbers, and documented cold-chain handling from dispatch to delivery.
Milo-Lab supplies tesamorelin as 10mg single vials, a 50mg kit (5 x 10mg) and a 100mg kit (10 x 10mg), each with a certificate of analysis, shipping to researchers across Thailand.
Reconstitution and Storage
Reconstitution: use bacteriostatic water; swirl gently until fully dissolved, do not shake. After reconstitution: store refrigerated and use within 30 days.
Researchers investigating related growth-hormone-axis peptides can browse the Performance & Growth category, which groups tesamorelin alongside CJC-1295, ipamorelin, and sermorelin.
Research Use Only
Tesamorelin supplied by Milo-Lab is sold strictly as a research chemical for laboratory use by qualified researchers. While the compound carries an FDA-approved clinical indication (Egrifta) for HIV-associated lipodystrophy, the research vials sold here are unbranded material intended for laboratory investigation, not for human self-administration outside clinical supervision. Nothing in this article is medical advice.
See the full tesamorelin profile for pack details, FAQs and complete study citations.
Interested in the peptides discussed in this article?
Browse our full catalog of research-grade peptides or contact us for personalized recommendations.